NEJM (@NEJM) / X

Pinned

Leishmaniasis is a parasitic infection that is transmitted by sand flies and caused by multiple leishmania species, with different species capable of causing cutaneous, visceral, or mucosal forms of the disease. 👉 nej.md/3TnJBKg Cutaneous leishmaniasis usually

An informative graphic on the pathogenesis, clinical presentation, and treatment of mucosal leishmaniasis caused by Leishmania braziliensis infection. There are maps highlighting affected countries in the Americas. The graphic includes illustrations of cutaneous and mucosal leishmaniasis symptoms and treatment methods, depicting skin lesions and mucosal damage. Treatment options listed involve pharmacological interventions.

Original Article: Immediate Ambulatory Electrocardiographic Monitoring in Syncope (ASPIRED trial) nej.md/4wH7SJh #ESCCongress | @escardio

The image shows Kaplan–Meier curves for death from any cause and detection of clinically significant cardiac arrhythmias. Panel A shows cumulative all-cause mortality in the intervention group and in the standard-care group. Panel B shows the cumulative probability of detection of a clinically significant cardiac arrhythmia in the two groups.

NEJM

@NEJM

9h

In a new NEJM Voices blog post, Don Dizon, MD, reflects on the profound shock of a colleague’s cancer diagnosis. Read “When Cancer Hits Home” and sign up for email alerts: nej.md/4i0fMK1

A photo from the NEJM Voices blog post "When Cancer Hits Home" by Don Dizon, M.D. In the photo, Dr. Dizon and Dr. Rachna Shroff sit in front of a sign that reads, "The Women in Oncology Awards." Dr. Shroff is wearing a lei (the photo was taken in Hawaii).

#ESCCongress 2026 Round Up: 18 articles were simultaneously published in NEJM and presented at this year’s @escardio Congress in Munich. Original Article: Eplontersen for Transthyretin Amyloid Cardiomyopathy (phase 3 CARDIO-TTRansform trial) nej.md/4wBEGTO

A graph showing the mean cumulative event rate (per 100 patients) for primary end-point events (death from cardiovascular causes and recurrent cardiovascular events) up to week 140.

Original Article: Survodutide Once Weekly for the Treatment of Adults with Obesity (phase 3 SYNCHRONIZE-1 trial) nej.md/4x7Tafs #Endocrinology

Three figures show the effects of survodutide on body weight. Panel A shows the percent change in body weight from baseline to week 76, derived from an analysis-of-covariance model, for the treatment-regimen estimand. Panel B shows the percent change in body weight according to the number of weeks since randomization, derived from an analysis with a mixed model for repeated measures, and the percentage of participants who had weight reduction of at least 5% from baseline to week 76, both for the efficacy estimand. Panel C shows the percentages of participants who had weight reduction of at least 5%, at least 10%, at least 15%, or at least 20% from baseline to week 76 for the treatment-regimen estimand.